All In Biotech

Free tool

FAERS Monitor: Vabysmo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761235 or its brand name (Vabysmo, Faricimab-Svoa). Reports on generic versions are filed under their own applications.

Reports

8,868

Serious

4,784

54% of reports

Hospitalization

539

Death reported

513

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use2,963
  • no adverse event1,970
  • retinal thickening1,471
  • visual impairment856
  • optical coherence tomography abnormal776
  • death466
  • drug ineffective380
  • eye inflammation360
  • uveitis353
  • visual acuity tests abnormal346
  • visual acuity reduced332
  • blindness275
  • vitritis269
  • endophthalmitis266
  • vision blurred245

Reports by year received

View as table
YearReports
20193
20201
202110
2022254
2023771
20243,756
20251,735
20262,338

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,291 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
optical coherence tomography abnormalSignal77621923.617520.91,659,481
retinal thickeningSignal1,47117542.415150.83,072,753
visual acuity tests abnormalSignal3463910.13298.2509,259
vitritisSignal269403.0354.891,879
endophthalmitisSignal266110.097.427,360
eye inflammationSignal36093.083.831,439
uveitisSignal35363.357.121,050
no adverse eventSignal1,97026.125.147,342
visual acuity reducedSignal33223.921.57,214
visual impairmentSignal85616.515.512,428
blindnessSignal27516.114.33,864
off label useSignal2,9638.07.819,016
vision blurredSignal2454.23.7606
death4661.31.230
drug ineffective3800.70.659

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.